CSIMarket
 
Enovis Corp  (ENOV)
Other Ticker:  
 
 
Price: $59.5800 $0.29 0.489%
Day's High: $59.74 Week Perf: -0.3 %
Day's Low: $ 58.44 30 Day Perf: -0.43 %
Volume (M): 453 52 Wk High: $ 66.14
Volume (M$): $ 26,960 52 Wk Avg: $55.44
Open: $58.96 52 Wk Low: $43.04



 Market Capitalization (Millions $) 3,432
 Shares Outstanding (Millions) 58
 Employees 36
 Revenues (TTM) (Millions $) 1,506
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 131

Enovis Corp
Enovis Corporation is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth eXcellence business system (eEGXe), a set of tools, processes, and culture, to continuously improve our ability to enable great patient outcomes and to drive and fuel growth.


   Company Address: 2711 Centerville Road, Wilmington, 19808 DE
   Company Phone Number: 252-9160   Stock Exchange / Ticker: NYSE ENOV
   ENOV is expected to report next financial results on February 29, 2024.


Customers recorded net loss Customers recorded net loss



• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Empowering Osteoarthritis Patients: Enovis Unveils the DonJoy ROAM OA Knee Brace for Ultimate Comfort and Effectiveness

Published Thu, Jan 25 2024 1:30 PM UTC

Enovis Introduces the DonJoy ROAM OA Knee Brace: The Future of Unloader BracesEnovis, a leading healthcare technology company, has recently unveiled an impressive breakthrough in the field of knee braces with the introduction of the DonJoy ROAM OA Knee Brace. This latest innovation in unloader braces promises to revolutionize the way individuals suffering from osteoarthritis...

Merger and Acquisition

Enovis Redefines Medical Technology Landscape with LimaCorporate S.p.A Acquisition

Published Wed, Jan 3 2024 11:00 AM UTC



WILMINGTON, Del., Jan. 03, 2024 - Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, announced today the successful completion of its acquisition of LimaCorporate S.p.A, a privately held global orthopedic leader renowned for its groundbreaking implant solutions. This significant milestone further solidifies Enovis' position as ...

Enovis Corp

Medical Equipment Firm Enovis Corp Sees Alarmingly Swelled Deficits in Q2 2023: A Contrast to Sector-Wide Revenue Boost


Introduction
Enovis Corp, a company in the Medical Equipment & Supplies sector, has recently experienced a decline in its stock price over the last five trading days. This drop follows the release of the company's Jun 30, 2023 report, which revealed a significant deterioration in revenue and net loss per share. This article aims to shed light on Enovis Corp's recent financial performance and analyze its implications for investors.
Disastrous Jun 2023 Report
Enovis Corp's Jun 30, 2023 report paints a concerning picture for the company. The report indicates that its revenue has decreased by a substantial 58.138% to $428.36 million compared to the same period last year. Additionally, its net loss per share has surged to $-0.18, in sharp contrast to the prior reporting season.

Enovis Corp

Promising future amid industry challenges for Enovis Corp

Despite Enovis Corp's recent disappointing financial results, there are still plenty of reasons for investors to remain bullish about the company's prospects.
Firstly, it's important to note that Enovis Corp is far from alone in its struggles within the biotechnology and pharmaceuticals sector. Many companies in this space face significant challenges when it comes to developing new products and bringing them to market, and setbacks like those experienced by Enovis Corp in Q1 2023 are not uncommon.






 

Enovis's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com